Benazepril Hydrochloride

CHEMBL1694 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

460.9 g/mol

LogP

—

Phase

4

The hydrochloride salt of benazepril, the standard commercial formulation of this ACE inhibitor for treating hypertension and heart failure. It also provides kidney-protective effects in diabetic kidney disease.

Moleküler Ağırlık

460,9000 g/mol

TPSA

95,90 Å²

Terapötik Alanlar

Hypertension

Etki Mekanizması

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl

InChI

InChI=1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1

Molecular Formula

C24H29ClN2O5

HBD / HBA

3 / 6

Döndürülebilir Bağlar

10

Ağır Atomlar

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrochloride salt of benazepril, the standard commercial formulation of this ACE inhibitor for treating hypertension and heart failure. It also provides kidney-protective effects in diabetic kidney disease.

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Yes, Benazepril Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1694. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5362123. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Benazepril Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C24H29ClN2O5
Eş Anlamlılar: 5

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Benazepril Hydrochloride

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget